Tags

Type your tag names separated by a space and hit enter

Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population.
Int J Geriatr Psychiatry. 2004 Jun; 19(6):509-15.IJ

Abstract

The management of dementia in Alzheimer's disease has dramatically changed since the development of anti-dementia drugs. However, there is limited information available regarding the bio-medical aspects of the differing drugs; particularly relating to adults with intellectual disability. Indeed the information available for the intellectual disabled population is limited to adults with Down syndrome. This review highlights the important pharmacological and clinical aspects of donepezil, rivastigmine, galantamine and memantine and supports the view that such drugs play an important part in the management of dementia in adults with intellectual disability. Future clinical and research issues are discussed.

Authors+Show Affiliations

The Greenfields, Birmingham, UK. vprasher@compuserve.com

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

15211527

Citation

Prasher, V P.. "Review of Donepezil, Rivastigmine, Galantamine and Memantine for the Treatment of Dementia in Alzheimer's Disease in Adults With Down Syndrome: Implications for the Intellectual Disability Population." International Journal of Geriatric Psychiatry, vol. 19, no. 6, 2004, pp. 509-15.
Prasher VP. Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population. Int J Geriatr Psychiatry. 2004;19(6):509-15.
Prasher, V. P. (2004). Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population. International Journal of Geriatric Psychiatry, 19(6), 509-15.
Prasher VP. Review of Donepezil, Rivastigmine, Galantamine and Memantine for the Treatment of Dementia in Alzheimer's Disease in Adults With Down Syndrome: Implications for the Intellectual Disability Population. Int J Geriatr Psychiatry. 2004;19(6):509-15. PubMed PMID: 15211527.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population. A1 - Prasher,V P, PY - 2004/6/24/pubmed PY - 2004/7/24/medline PY - 2004/6/24/entrez SP - 509 EP - 15 JF - International journal of geriatric psychiatry JO - Int J Geriatr Psychiatry VL - 19 IS - 6 N2 - The management of dementia in Alzheimer's disease has dramatically changed since the development of anti-dementia drugs. However, there is limited information available regarding the bio-medical aspects of the differing drugs; particularly relating to adults with intellectual disability. Indeed the information available for the intellectual disabled population is limited to adults with Down syndrome. This review highlights the important pharmacological and clinical aspects of donepezil, rivastigmine, galantamine and memantine and supports the view that such drugs play an important part in the management of dementia in adults with intellectual disability. Future clinical and research issues are discussed. SN - 0885-6230 UR - https://www.unboundmedicine.com/medline/citation/15211527/Review_of_donepezil_rivastigmine_galantamine_and_memantine_for_the_treatment_of_dementia_in_Alzheimer's_disease_in_adults_with_Down_syndrome:_implications_for_the_intellectual_disability_population_ L2 - https://doi.org/10.1002/gps.1077 DB - PRIME DP - Unbound Medicine ER -